SCHEMBL3401326

SCHEMBL3401326

Nc1ccc(C(=O)NCCN2CCCCC2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.74
▸ CYP2D6 P10635 1/20 0.74
▸ CYP2C9 P11712 1/20 0.74
▸ ALDH1A1 P00352 3/20 0.69
▸ NPSR1 Q6W5P4 1/20 0.69
▸ CD274 Q9NZQ7 1/20 0.69
▸ POLB P06746 1/20 0.64
▸ HPGD P15428 2/20 0.63
▸ KDM4E B2RXH2 1/20 0.63
▸ MEN1 O00255 1/20 0.63
▸ KMT2A Q03164 1/20 0.63
▸ GLA P06280 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ EPHX2 P34913 1/20 0.57
▸ HDAC2 Q92769 1/20 0.57
▸ HDAC8 Q9BY41 1/20 0.57
▸ HDAC6 Q9UBN7 1/20 0.57
▸ CA12 O43570 1/20 0.57
▸ CA9 Q16790 1/20 0.57
▸ HRH3 Q9Y5N1 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3408343 0.98 ALDH1A1 (0.71) CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1
SCHEMBL22837224 0.90 CD274 (0.62) CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1
SCHEMBL18874231 0.88 CD274 (0.59) CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1
SCHEMBL29605727 0.88 CYP1A2 (0.74) CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1
SCHEMBL30969330 0.86 ALDH1A1 (0.71) CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1
SCHEMBL4488723 0.86 CYP1A2 (0.76) CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1
SCHEMBL9199198 0.85 LMNA (0.67) CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1
SCHEMBL19634394 0.85 CYP1A2 (0.70) CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1
SCHEMBL3543817 0.85 CD274 (0.92) CYP1A2CYP2D6ALDH1A1CD274POLB
SCHEMBL14329888 0.85 ALDH1A1 (0.94) CYP1A2CYP2D6CYP2C9ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2252296-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES Wyeth LLC (US) 2010-11-24 — — EP disclosed
WO-2009091788-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-23 — — WO disclosed
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES MTOR, PIK3CA, PIK3CD CYP1A2 2632/4885CYP2D6 1298/4885CYP2C9 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback